[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2015160470A3 - Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease - Google Patents

Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease Download PDF

Info

Publication number
WO2015160470A3
WO2015160470A3 PCT/US2015/021578 US2015021578W WO2015160470A3 WO 2015160470 A3 WO2015160470 A3 WO 2015160470A3 US 2015021578 W US2015021578 W US 2015021578W WO 2015160470 A3 WO2015160470 A3 WO 2015160470A3
Authority
WO
WIPO (PCT)
Prior art keywords
formyl
diagnosis
treatment
disease
nadph production
Prior art date
Application number
PCT/US2015/021578
Other languages
French (fr)
Other versions
WO2015160470A2 (en
Inventor
Joshua D. Rabinowitz
Jing Fan
Gregory S. DUCKER
Original Assignee
The Trustees Of Princeton University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Princeton University filed Critical The Trustees Of Princeton University
Publication of WO2015160470A2 publication Critical patent/WO2015160470A2/en
Publication of WO2015160470A3 publication Critical patent/WO2015160470A3/en
Priority to US15/266,596 priority Critical patent/US11369588B2/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to the recognition of a 10-formyl-THF pathway for producing NADPH, and to the use of that recognition in the diagnosis and treatment of cancer and metabolic disease, and in the development of new antineoplastic agents and/or regimens, and new therapeutics for treating metabolic disease.
PCT/US2015/021578 2014-03-20 2015-03-19 Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease WO2015160470A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/266,596 US11369588B2 (en) 2014-03-20 2016-09-15 NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968036P 2014-03-20 2014-03-20
US61/968,036 2014-03-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/266,596 Continuation-In-Part US11369588B2 (en) 2014-03-20 2016-09-15 NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease

Publications (2)

Publication Number Publication Date
WO2015160470A2 WO2015160470A2 (en) 2015-10-22
WO2015160470A3 true WO2015160470A3 (en) 2015-12-10

Family

ID=54324695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/021578 WO2015160470A2 (en) 2014-03-20 2015-03-19 Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease

Country Status (1)

Country Link
WO (1) WO2015160470A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168150A2 (en) * 2015-04-13 2016-10-20 The Board Of Regents Of The University Of Texas System Treatment for cancer metastasis
WO2017156362A1 (en) 2016-03-11 2017-09-14 President And Fellows Of Harvard College Modulating t cell survival by targeting the one-carbon metabolic pathway
KR20200103662A (en) * 2017-11-22 2020-09-02 콘서트 파마슈티컬즈, 인크. Deuterated analogs of D-serine and uses thereof
CN111912826B (en) * 2020-06-22 2024-03-01 上海氘峰医疗科技有限公司 Method for evaluating efficacy of antitumor drug at cellular level
CN115166067B (en) * 2022-05-26 2023-12-26 中国农业科学院北京畜牧兽医研究所 Peptide fragment composition for relatively quantitatively analyzing pig 10-formyl tetrahydrofolate dehydrogenase ALDH1L1 and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070249545A1 (en) * 2004-08-27 2007-10-25 Rodriguez-Lopez Jose N Dihydrofolate reductase inhibition by epigallocatechin gallate compounds
US20130273533A1 (en) * 2004-02-20 2013-10-17 The Regents Of The University Of California Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273533A1 (en) * 2004-02-20 2013-10-17 The Regents Of The University Of California Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
US20070249545A1 (en) * 2004-08-27 2007-10-25 Rodriguez-Lopez Jose N Dihydrofolate reductase inhibition by epigallocatechin gallate compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANGUERA ET AL.: "Regulation of Folate-mediated One-carbon Metabolism by 10-Formyltetrahydrofolate Dehydrogenase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 27, 7 July 2006 (2006-07-07), pages 18335 - 18342, XP055239523, ISSN: 0021-9258 *
BIRRELL ET AL.: "Investigation of NADH Binding, Hydride Transfer, and NAD+ Dissociation during NADH Oxidation by Mitochondrial Complex I Using Modified Nicotinamide Nucleotides", BIOCHEMISTRY, vol. 52, no. 23, 17 May 2013 (2013-05-17), pages 4048 - 4055, XP055239521, ISSN: 0006-2960 *
FAN ET AL.: "Quantitative flux analysis reveals folate-dependent NADPH production", NATURE, vol. 510, no. 7504, 12 June 2014 (2014-06-12), pages 298 - 302, XP055239524, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
WO2015160470A2 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
IL280530A (en) Aadc polynucleotides for the treatment of parkinson's disease
PH12017500153A1 (en) Compositions and methods of use for treating metabolic disorders
JP2016515522A5 (en)
AU359599S (en) Dumbbell
IL276733A (en) Use of eribulin in the treatment of cancer
WO2015120372A3 (en) Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
WO2015160470A3 (en) Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease
WO2016089886A3 (en) Methods for treating dry eye disease by administering an il-6r antagonist
WO2015138532A3 (en) Methods for the treatment of kidney fibrosis
WO2015179835A3 (en) Mit biomarkers and methods using the same
MX2019000677A (en) B-cell-mimetic cells.
EP3702470A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
MX2018014129A (en) Pharmaceutical composition comprising eteplirsen.
PH12016502311A1 (en) Omega-3 analogues
PH12017500923A1 (en) New dosage and use of a a2a antagonist
WO2015134603A3 (en) Methods for treating cancer
JP2017516883A5 (en)
TWD191481S (en) Exercise bike control panel
WO2016005823A3 (en) Compositions for treating skin conditions
UA99456U (en) Needle for acupuncture
CN302103860S (en) door
CN302241295S (en) Access Control Machine (S500)
TH1601002847A (en) 2,6-substituted purine derivatives and their use in the treatment of disorders that has increased in number more than usual
MY180540A (en) Composition containing apomorphine and a divalent metal cation
CR20140338S (en) INDUSTRIAL ABDOMINAL BANDAGE MODEL

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15779262

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15779262

Country of ref document: EP

Kind code of ref document: A2